澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CLARITY PHARMACEUTICALS LTD

2.110

-0.040-1.86%

成交量：283.66萬

成交額：597.27萬

市值：7.85億

市盈率：-7.48

高：2.160

開：2.100

低：2.080

收：2.150

52周最高：5.870

52周最低：1.970

股本：3.72億

流通股本：2.74億

量比：1.24

換手率：1.03%

股息：- -

股息率：- -

每股收益(TTM):-0.282

每股收益(LYR):-0.201

淨資產收益率：-53.45%

總資產收益率：-30.54%

市淨率：3.37

市盈率(LYR):-10.48

資料載入中...

總覽公司新聞資訊公告

Clarity Pharmaceuticals與Nucleus Radiopharma簽署Cu-64 SAR-Bispsma商業化生產協議

Clarity Pharmaceuticals與Theragenics簽署銅-64大規模生產供應協議

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CU6.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":2.11,"timestamp":1781071920000,"preClose":2.15,"halted":0,"volume":2836618,"delay":0,"changeRate":-0.018604651162790715,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.282253,"marketStatus":"未開盤","change":-0.04,"latestTime":"06-10 16:12:00 AEST","open":2.1,"high":2.16,"low":2.08,"amount":5972692,"amplitude":0.037209,"askPrice":2.14,"askSize":1157,"bidPrice":2.09,"bidSize":18754,"shortable":3,"etf":0,"ttmEps":-0.282253,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1781136000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.15,"openAndCloseTimeList":[[1781049600000,1781071200000]],"volumeRatio":1.236834,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CU6.AU","preClose":2.15,"auctionPrice":2.11,"auctionVolume":265976,"auction":3,"marketStatus":"盘后竞价","timestamp":1781071800135}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-30.54%","roe":"-53.45%","lyrEps":-0.201427,"volumeRatio":1.236834,"shares":372030071,"dividePrice":0,"high":2.16,"amplitude":0.037209,"preClose":2.15,"low":2.08,"week52Low":1.97,"pbRate":"3.37","psRate":"74.20","week52High":5.87,"institutionHeld":0,"latestPrice":2.11,"committee":0.883783,"eps":-0.282253,"divideRate":0,"volume":2836618,"delay":0,"ttmEps":-0.282253,"open":2.1,"prevYearClose":3.38,"prevWeekClose":2.25,"prevMonthClose":2.49,"prevQuarterClose":3.1,"fiveDayClose":2.36,"twentyDayClose":2.85,"sixtyDayClose":3.83,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1145830308","title":"Clarity Pharmaceuticals與Nucleus Radiopharma簽署Cu-64 SAR-Bispsma商業化生產協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1145830308","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145830308?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 06:35","pubTimestamp":1776119715,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd近日宣布，已与Nucleus Radiopharma达成一项重要合作，双方正式签署了关于放射性药物Cu-64 SAR-Bispsma的商业化生产协议。该协议的签署标志着Clarity在核医学领域的产业化进程迈出关键一步，为其前列腺癌靶向诊疗产品的规模化供应奠定基础。通过此次合作，Nucleus Radiopharma将依托其符合药品生产质量管理规范的生产设施，为Clarity提供符合临床级标准的Cu-64 SAR-Bispsma放射性药物。Cu-64 SAR-Bispsma作为一种新型靶向放射诊疗药物，可通过PET成像技术精准定位前列腺癌病灶，同时具备治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162626167","title":"Clarity Pharmaceuticals與Theragenics簽署銅-64大規模生產供應協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1162626167","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162626167?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 06:25","pubTimestamp":1774391113,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd（以下简称Clarity）近日宣布，已与Theragenics公司达成一项关于铜-64（Copper-64）的大规模生产供应协议。该协议的签署标志着双方在放射性药物领域的合作迈出了重要一步，为Clarity在癌症诊断和治疗方面的产品开发提供了稳定的原材料保障。\n铜-64作为一种重要的医用放射性同位素，在正电子发射断层扫描（PET）成像中具有广泛应用前景。此次大规模供应协议的达成，不仅有助于提升Clarity核心产品的生产能力，也将进一步巩固其在精准医疗领域的市场地位。双方表示，将通过紧密合作确保铜-64的稳定供应，满足未来市场需求的增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}